- Home
- ANL vs CUE Comparison
ANL vs CUE Comparison
Compare ANL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- CUE
- Stock Information
- Founded
- ANL 2004
- CUE 2014
- Country
- ANL Cayman Islands
- CUE United States
- Employees
- ANL N/A
- CUE N/A
- Industry
- ANL
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- CUE Health Care
- Exchange
- ANL Nasdaq
- CUE Nasdaq
- Market Cap
- ANL 61.8M
- CUE 56.1M
- IPO Year
- ANL 2023
- CUE 2018
- Fundamental
- Price
- ANL $1.79
- CUE $0.75
- Analyst Decision
- ANL Hold
- CUE Strong Buy
- Analyst Count
- ANL 1
- CUE 2
- Target Price
- ANL N/A
- CUE $3.00
- AVG Volume (30 Days)
- ANL 11.3K
- CUE 187.3K
- Earning Date
- ANL 10-21-2025
- CUE 11-13-2025
- Dividend Yield
- ANL N/A
- CUE N/A
- EPS Growth
- ANL N/A
- CUE N/A
- EPS
- ANL N/A
- CUE N/A
- Revenue
- ANL N/A
- CUE $8,286,000.00
- Revenue This Year
- ANL N/A
- CUE N/A
- Revenue Next Year
- ANL N/A
- CUE $13.27
- P/E Ratio
- ANL N/A
- CUE N/A
- Revenue Growth
- ANL N/A
- CUE N/A
- 52 Week Low
- ANL $1.10
- CUE $0.54
- 52 Week High
- ANL $3.89
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- ANL 55.55
- CUE 54.66
- Support Level
- ANL $1.70
- CUE $0.69
- Resistance Level
- ANL $1.82
- CUE $0.73
- Average True Range (ATR)
- ANL 0.09
- CUE 0.04
- MACD
- ANL -0.00
- CUE 0.01
- Stochastic Oscillator
- ANL 60.33
- CUE 85.70
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.